MYRIAD GENETICS, INC.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | $0 | $967.8M | $257.4M |
| FY2022 | $0 | $885.8M | $56.9M |
| FY2023 | $38.5M | $783.2M | $132.1M |
| FY2024 | $39.6M | $701.1M | $102.4M |
| FY2025 | $119.9M | $368.0M | $149.6M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | $0 | $967.8M | $257.4M |
| FY2022 | $0 | $885.8M | $56.9M |
| FY2023 | $38.5M | $783.2M | $132.1M |
| FY2024 | $39.6M | $701.1M | $102.4M |
| FY2025 | $119.9M | $368.0M | $149.6M |